Physician profile
Mark Morici
NPI 1316913676
$4,124.60
in general payments reported to CMS, 2019-2025
28 companies · $772 in 2025
The $772 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $377 · 2021: $720 · 2022: $612 · 2023: $443 · 2024: $889 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $953.32 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $825.92 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $431.06 | 2025 | Jornay Pm |
| Corium, LLC | $245.74 | 2021-2025 | Azstarys |
| Neos Therapeutics, Lp | $243.00 | 2019-2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $234.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $184.18 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $157.41 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Pfizer INC. | $129.59 | 2022-2024 | |
| Genentech USA, INC. | $119.84 | 2019-2021 | |
| Adlon Therapeutics L.P. | $119.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.16 | 2019-2021 | |
| Sobi, INC | $51.61 | 2020-2022 | |
| Phadia US INC. | $44.90 | 2019-2024 | Immunocap |
| Seqirus USA INC | $42.01 | 2022-2025 | Flucelvax |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.16 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $23.80 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $22.93 | 2025 | Neffy |
| Cipher Pharmaceuticals US LLC | $22.01 | 2025 | Spinosad, Natroba |
| Kyowa Kirin, INC. | $21.47 | 2025 | |
| Verrica Pharmaceuticals INC. | $20.50 | 2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $19.80 | 2024 | Dupixent |
| Vertical Pharmaceuticals, LLC | $18.88 | 2025 | Relexxii |
| Cranial Technologies, INC | $15.18 | 2024 | Doc Band |
| Novartis Pharmaceuticals Corporation | $14.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2024 | Zoryve |
| Mylan Pharmaceuticals INC. | $12.78 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Morici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.